



1088 '03 MAR -7 P2:12

MAR 06 2003

Taro Research Institute Ltd.
Attention: Avraham Yacobi, Ph.D.
Five Skyline Drive
Hawthorne, NY 10532

Docket No. 02P-0394/CPI

Dear Dr. Yacobi:

This letter contains a correction to the listed drug cited in the petition response dated November 25, 2002. This is a response to your petition filed on September 4, 2002, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug product: Amiodarone Hydrochloride Tablets, 300 mg. The listed drug product to which you refer in your petition is Amiodarone Hydrochloride Tablets, 400 mg, approved under ANDA 75-315 held by Eon Laboratories Manufacturing, Inc. Your petition cited two drugs of reference. Please be advised that, pursuant to 21 CFR 314.93, the petitioner shall identify a listed drug as the drug of reference for requested changes.

Your request involves a change in strength from that of the listed drug product (i.e., from 400 mg to 300 mg). The change you request is the type of change that is authorized under the Federal Food, Drug, and Cosmetic Act (Act).

We have reviewed your petition under Section 505(j)(2)(C) of the Act and have determined that it is approved. This letter represents the Food and Drug Administration's (FDA) determination that an ANDA may be submitted for the above-referenced drug product.

Under Section 505(j)(2)(C)(i) of the Act, the FDA must approve a petition seeking a strength that differs from the strength of the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing strength.

The FDA finds that the change in the strength for the specific proposed drug product does not pose questions of safety or effectiveness because the proposed product (amiodarone hydrochloride tablets, 300 mg) is an intermediate strength and the uses, dose, and route of administration of the proposed drug product are the same as that of the listed drug product. The FDA concludes, therefore, that investigations are not necessary in this instance. In addition, if shown to meet bioavailability requirements, the proposed drug product can be expected to have the same therapeutic effect as the listed reference drug product.

02P-0394

RAV2

02P-0394/CP1

Taro Research Institute Ltd .

The approval of this petition to allow an ANDA to be submitted for the above-referenced drug product does not mean that the FDA has determined that an ANDA will be approved for the drug product. The determination of whether an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the FDA.

To permit review of your ANDA submission, you must submit all information required under Sections 505(j)(2)(A) and (B) of the Act. To be approved, the drug product will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. Please be advised that the type of evidence necessary to meet the current bioavailability requirements is not evaluated during the petition process. The information will be evaluated during the review of your ANDA. We suggest that you submit your protocol for this drug product to the Office of Generic Drugs, Division of Bioequivalence, prior to the submission of your ANDA. During the review of your application, the FDA may require the submission of additional information.

The listed drug product to which you refer in your ANDA must be the drug product upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,



Gary J. Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research